LABORATORY CORE

本计划项目的实验室核心的任务是提供一致和可靠的“最新状态”。 ART法检测多发性骨髓瘤患者血清和血浆中的细胞因子 在假说驱动的临床试验中进行调查，以评估症状、疾病 (癌症)和癌症治疗。通过以下方式在一个位置协调和执行细胞因子分析 一个单独的实验室，在经验丰富的主任的指导下，将消除变异性和 分析结果不一致，并提供统一的结果，可在不同项目之间进行比较。 实验室核心与服务相关的具体目标是： 1.对所有四个项目的研究对象的所有标本进行处理、存档和存储； 2.用Luminex Multiplex细胞珠阵列(Multiplex)检测血清/血浆细胞因子水平 测定或酶免疫吸附测定； 3.通过检测健康献血者的样本，建立每个细胞因子研究的正常范围； 4.为所有项目负责人、统计员、护理和实验室提供科学和技术指导 确保工作的临床和生物学相关性和适当的解释的人员 数据。 在多发性骨髓瘤中，核因子-kB呈结构性活性，血浆IL-6和血管生成水平升高 血管内皮细胞生长因子和碱性成纤维细胞生长因子与患者的高肿瘤负担相关。实验室核心也 除了服务使命之外，还提出了以假体为导向的具体目标。我们将评估 血管生成细胞因子与多发性骨髓瘤患者临床疗效的关系 诱导疗法。我们假设对沙利度胺或沙利度胺诱导治疗有反应的患者 Bortezomib(详见项目I和4)将降低血管生成细胞因子bFGF的水平 和血管内皮生长因子。

The mission of the Laboratory Core of this Program Project is to provide consistent and reliable "state-ofthe- art" assays to measure cytokines in serum and plasma samples from of patients with multiple myeloma being investigated in hypothesis-driven clinical trials to assess the relationship between symptoms, disease (cancer), and therapy for cancer. Having the cytokine assays coordinated and performed at one location, by a single laboratory and under the direction of an experienced director, will eliminate variability and inconsistency in assay findings and provide uniform results that can be compared across projects. The service-related Specific Aims of the Laboratory Core are to: 1. Process, archive, and store all specimens from the study subjects of all four projects; 2. Measure serum/plasma cytokine levels by using Luminex Multiplex Cytometric Bead Array (Multiplex) assays or enzyme immunosorbent assays; 3. Establish normal ranges for each cytokine to be studied by assaying samples from healthy donors; 4. Provide scientific and technical guidance to all project leaders, statisticians, and nursing and laboratory personnel to ensure the clinical and biological relevance of the work and appropriate interpretation of the data. In multiple myeloma, NF-KB is constitutively active and the elevated plasma level of IL-6 and angiogenic factors, VEGF and bFGF are correlated with high tumor burden of patients. The Laboratory Core also proposes a hj'pothesis-driven specific aim in addition to its service mission. We will evaluate angiogenic cytokines in relation to the clinical response of patients with multiple myeloma receiving induction therapy. We hypothesize that patients responding to induction therapy with thalidomide or bortezomib (detailed in Projects i and 4) would have a reduction in the level of angiogenic cytokines bFGF and VEGF.